Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis
B Galling, A Roldan, K Hagi, L Rietschel… - World …, 2017 - Wiley Online Library
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature
search and a random effects meta‐analysis of randomized trials comparing augmentation
with a second antipsychotic vs. continued antipsychotic monotherapy in schizophrenia. Co‐
primary outcomes were total symptom reduction and study‐defined response. Antipsychotic
augmentation was superior to monotherapy regarding total symptom reduction (16 studies …
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature
search and a random effects meta‐analysis of randomized trials comparing augmentation
with a second antipsychotic vs. continued antipsychotic monotherapy in schizophrenia. Co‐
primary outcomes were total symptom reduction and study‐defined response. Antipsychotic
augmentation was superior to monotherapy regarding total symptom reduction (16 studies …
Antipsychotic augmentation vs. monotherapy in schizophrenia
B Galling, M Zink - 2017 - katalog.ub.uni-heidelberg.de
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature
search and a random effects meta‐analysis of randomized trials comparing augmentation
with a second antipsychotic vs. continued antipsychotic monotherapy in schizophrenia. Co‐
primary outcomes were total symptom reduction and study‐defined response. Antipsychotic
augmentation was superior to monotherapy regarding total symptom reduction (16 studies …
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature
search and a random effects meta‐analysis of randomized trials comparing augmentation
with a second antipsychotic vs. continued antipsychotic monotherapy in schizophrenia. Co‐
primary outcomes were total symptom reduction and study‐defined response. Antipsychotic
augmentation was superior to monotherapy regarding total symptom reduction (16 studies …
以上显示的是最相近的搜索结果。 查看全部搜索结果